Literature DB >> 16761159

Expression of P-glycoprotein in lymphocytes from children with nephrotic syndrome, depending on their steroid response.

Anna Wasilewska1, Walentyna Zoch-Zwierz, Miroslawa Pietruczuk, Grzegorz Zalewski.   

Abstract

The aim of this study was to examine the expression of P-glycoprotein (P-gp) in CD3 lymphocytes of children with nephrotic syndrome (NS) in relation to their clinical response to glucocorticoid (GC) treatment. The examinations were performed on two groups. The study group (I) consisted of 88 children aged 2.0-20.0 years with NS, divided according to their clinical response to GC: NFR-non-frequent relapse NS; FR-frequent relapse NS; SD-steroid-dependent NS. The control group (II) consisted of 18 healthy children never treated with GC. We measured P-gp expression on CD3 lymphocytes of patients with NS using a flow cytometry assay. The CD3/P-gp was significantly higher than in controls. The difference was higher in SD (P=0.0001) and FR - (P=0.0002) group. The difference in NFR was smaller. Mean CD3/P-gp (in percent) was twice as high in SD children than in NFR, and the difference, as between FR and NFR, was statistically significant (P<0.01). Worse response to GC or dependency may be due to overexpression of P-gp. Further examinations are necessary to establish whether increased P-gp activity is a result of MDR-1 polymorphism and to determine GC response, or to ascertain if such activity is only a result of GC therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16761159     DOI: 10.1007/s00467-006-0187-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  27 in total

Review 1.  Multidrug resistance: molecular mechanisms and clinical relevance.

Authors:  V Ling
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

Review 2.  Glucocorticoid resistance in inflammatory bowel disease.

Authors:  R J Farrell; D Kelleher
Journal:  J Endocrinol       Date:  2003-09       Impact factor: 4.286

Review 3.  Corticosteroid resistance in other disease states and tissues.

Authors:  S J Lane; T H Lee
Journal:  Am J Respir Crit Care Med       Date:  1996-08       Impact factor: 21.405

4.  Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes.

Authors:  S D Hearing; M Norman; C S Probert; N Haslam; C M Dayan
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

5.  Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus.

Authors:  Shizuyo Tsujimura; Kazuyoshi Saito; Shingo Nakayamada; Kazuhisa Nakano; Yoshiya Tanaka
Journal:  Arthritis Rheum       Date:  2005-06

Review 6.  Modulators of multidrug resistance. Preclinical studies.

Authors:  J M Ford
Journal:  Hematol Oncol Clin North Am       Date:  1995-04       Impact factor: 3.722

7.  Early identification of frequent relapsers among children with minimal change nephrotic syndrome. A report of the International Study of Kidney Disease in Children.

Authors: 
Journal:  J Pediatr       Date:  1982-10       Impact factor: 4.406

8.  Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie.

Authors: 
Journal:  Arch Dis Child       Date:  1987-11       Impact factor: 3.791

9.  P-glycoprotein expression and function in circulating blood cells from normal volunteers.

Authors:  W T Klimecki; B W Futscher; T M Grogan; W S Dalton
Journal:  Blood       Date:  1994-05-01       Impact factor: 22.113

10.  The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children.

Authors: 
Journal:  J Pediatr       Date:  1981-04       Impact factor: 4.406

View more
  8 in total

1.  Polymorphisms of the MDR1 and MIF genes in children with nephrotic syndrome.

Authors:  Hyun Jin Choi; Hee Yeon Cho; Han Ro; So Hee Lee; Kyung Hee Han; Hyunkyung Lee; Hee Gyung Kang; Il Soo Ha; Yong Choi; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2011-05-08       Impact factor: 3.714

2.  P-Glycoprotein Activity in Steroid-Responsive vs. Steroid-Resistant Nephrotic Syndrome.

Authors:  Hassan S Badr; Mahmoud A El-Hawy; Mohammed A Helwa
Journal:  Indian J Pediatr       Date:  2016-05-19       Impact factor: 1.967

3.  Effects of the ABCB1 (1199G > A) Polymorphism on Steroid Sex Hormone-Induced P-Glycoprotein Expression, ATPase Activity, and Hormone Efflux.

Authors:  Rui Peng; Hong Zhang; Ying Zhang; Dan-Yun Wei
Journal:  Med Sci (Basel)       Date:  2015-12-01

4.  Pharmacogenomic markers of glucocorticoid response in the initial phase of remission induction therapy in childhood acute lymphoblastic leukemia.

Authors:  Vladimir Gasic; Branka Zukic; Biljana Stankovic; Dragana Janic; Lidija Dokmanovic; Jelena Lazic; Nada Krstovski; Vita Dolzan; Janez Jazbec; Sonja Pavlovic; Nikola Kotur
Journal:  Radiol Oncol       Date:  2018-09-11       Impact factor: 2.991

Review 5.  Membranous nephropathy complicated by immune thrombocytopenia treated with low-density lipoprotein apheresis: a case report and literature review.

Authors:  Keitaro Nishizawa; Tomohisa Yamashita; Yayoi Ogawa; Hironori Kobayashi
Journal:  CEN Case Rep       Date:  2021-07-21

6.  Detection of active P-glycoprotein in systemic lupus erythematosus patients with poor disease control.

Authors:  Bo Zhang; Ying Shi; Tie-Chi Lei
Journal:  Exp Ther Med       Date:  2012-08-16       Impact factor: 2.447

Review 7.  A PRISMA-compliant meta-analysis of MDR1 polymorphisms and idiopathic nephrotic syndrome: Susceptibility and steroid responsiveness.

Authors:  Shi-Sheng Han; Yan-Qiu Xu; Yan Lu; Xiang-Chen Gu; Yi Wang
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.817

Review 8.  Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome.

Authors:  Anne M Schijvens; Rob Ter Heine; Saskia N de Wildt; Michiel F Schreuder
Journal:  Pediatr Nephrol       Date:  2018-03-16       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.